162 related articles for article (PubMed ID: 8455432)
1. Liver-directed superparamagnetic iron oxide: quantitation of T2 relaxation effects.
Pouliquen D; Lucet I; Chouly C; Perdrisot R; Le Jeune JJ; Jallet P
Magn Reson Imaging; 1993; 11(2):219-28. PubMed ID: 8455432
[TBL] [Abstract][Full Text] [Related]
2. Superparamagnetic iron oxide nanoparticles as a liver MRI contrast agent: contribution of microencapsulation to improved biodistribution.
Pouliquen D; Perdrisot R; Ermias A; Akoka S; Jallet P; Le Jeune JJ
Magn Reson Imaging; 1989; 7(6):619-27. PubMed ID: 2630844
[TBL] [Abstract][Full Text] [Related]
3. Long circulating superparamagnetic particles with high T2 relaxivity.
Pochon S; Hyacinthe R; Terrettaz J; Robert F; Schneider M; Tournier H
Acta Radiol Suppl; 1997; 412():69-72. PubMed ID: 9240083
[TBL] [Abstract][Full Text] [Related]
4. Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study.
Okon E; Pouliquen D; Okon P; Kovaleva ZV; Stepanova TP; Lavit SG; Kudryavtsev BN; Jallet P
Lab Invest; 1994 Dec; 71(6):895-903. PubMed ID: 7807971
[TBL] [Abstract][Full Text] [Related]
5. Long-term imaging effects in rat liver after a single injection of an iron oxide nanoparticle based MR contrast agent.
Briley-Saebø K; Hustvedt SO; Haldorsen A; Bjørnerud A
J Magn Reson Imaging; 2004 Oct; 20(4):622-31. PubMed ID: 15390223
[TBL] [Abstract][Full Text] [Related]
6. Magnetic iron oxide particles coated with carboxydextran for parenteral administration and liver contrasting. Pre-clinical profile of SH U555A.
Lawaczeck R; Bauer H; Frenzel T; Hasegawa M; Ito Y; Kito K; Miwa N; Tsutsui H; Vogler H; Weinmann HJ
Acta Radiol; 1997 Jul; 38(4 Pt 1):584-97. PubMed ID: 9240682
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat.
Majumdar S; Zoghbi SS; Gore JC
Invest Radiol; 1990 Jul; 25(7):771-7. PubMed ID: 2391194
[TBL] [Abstract][Full Text] [Related]
8. RES-specific imaging of the liver and spleen with iron oxide particles designed for blood pool MR-angiography.
Bremer C; Allkemper T; Baermig J; Reimer P
J Magn Reson Imaging; 1999 Sep; 10(3):461-7. PubMed ID: 10508309
[TBL] [Abstract][Full Text] [Related]
9. Clearance of iron oxide particles in rat liver: effect of hydrated particle size and coating material on liver metabolism.
Briley-Saebo KC; Johansson LO; Hustvedt SO; Haldorsen AG; Bjørnerud A; Fayad ZA; Ahlstrom HK
Invest Radiol; 2006 Jul; 41(7):560-71. PubMed ID: 16772849
[TBL] [Abstract][Full Text] [Related]
10. Physical and biological characterization of superparamagnetic iron oxide- and ultrasmall superparamagnetic iron oxide-labeled cells: a comparison.
Sun R; Dittrich J; Le-Huu M; Mueller MM; Bedke J; Kartenbeck J; Lehmann WD; Krueger R; Bock M; Huss R; Seliger C; Gröne HJ; Misselwitz B; Semmler W; Kiessling F
Invest Radiol; 2005 Aug; 40(8):504-13. PubMed ID: 16024988
[TBL] [Abstract][Full Text] [Related]
11. Studying the effect of particle size and coating type on the blood kinetics of superparamagnetic iron oxide nanoparticles.
Roohi F; Lohrke J; Ide A; Schütz G; Dassler K
Int J Nanomedicine; 2012; 7():4447-58. PubMed ID: 22927759
[TBL] [Abstract][Full Text] [Related]
12. Superparamagnetic agents: physicochemical characteristics and preclinical imaging evaluation.
Benderbous S; Corot C; Jacobs P; Bonnemain B
Acad Radiol; 1996 Aug; 3 Suppl 2():S292-4. PubMed ID: 8796583
[No Abstract] [Full Text] [Related]
13. Biodistribution of ultrasmall iron oxide particles in the rat liver.
Van Beers BE; Sempoux C; Materne R; Delos M; Smith AM
J Magn Reson Imaging; 2001 Apr; 13(4):594-9. PubMed ID: 11276104
[TBL] [Abstract][Full Text] [Related]
14. Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism.
Pouliquen D; Le Jeune JJ; Perdrisot R; Ermias A; Jallet P
Magn Reson Imaging; 1991; 9(3):275-83. PubMed ID: 1881245
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 180549, by different routes of administration.
Bengele HH; Palmacci S; Rogers J; Jung CW; Crenshaw J; Josephson L
Magn Reson Imaging; 1994; 12(3):433-42. PubMed ID: 8007773
[TBL] [Abstract][Full Text] [Related]
16. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging.
Briley-Saebo K; Bjørnerud A; Grant D; Ahlstrom H; Berg T; Kindberg GM
Cell Tissue Res; 2004 Jun; 316(3):315-23. PubMed ID: 15103550
[TBL] [Abstract][Full Text] [Related]
17. T2 relaxation induced by clusters of superparamagnetic nanoparticles: Monte Carlo simulations.
Matsumoto Y; Jasanoff A
Magn Reson Imaging; 2008 Sep; 26(7):994-8. PubMed ID: 18479873
[TBL] [Abstract][Full Text] [Related]
18. Ferrimagnetic susceptibility contrast agents.
Bach-Gansmo T
Acta Radiol Suppl; 1993; 387():1-30. PubMed ID: 8390776
[TBL] [Abstract][Full Text] [Related]
19. Effects of spatial distribution on proton relaxation enhancement by particulate iron oxide.
Tanimoto A; Pouliquen D; Kreft BP; Stark DD
J Magn Reson Imaging; 1994; 4(5):653-7. PubMed ID: 7526912
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the magnetic properties of iron oxide nanoparticles used as contrast agent for MRI.
Pouliquen D; Perroud H; Calza F; Jallet P; Le Jeune JJ
Magn Reson Med; 1992 Mar; 24(1):75-84. PubMed ID: 1556931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
